IOVA

Company Overview — What Does IOVANCE BIOTHERAPEUTICS, INC. Do?

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. IOVANCE BIOTHERAPEUTICS, INC. (IOVA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Frederick G. Vogt and employs approximately 500 people, headquartered in Woodland Hills, California. With a market capitalization of $1.4B, IOVA is one of the notable companies in the Healthcare sector.

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Stock Rating — Reduce (April 2026)

As of April 2026, IOVANCE BIOTHERAPEUTICS, INC. receives a Reduce rating with a composite score of 34.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IOVA ranks #3,082 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, IOVANCE BIOTHERAPEUTICS, INC. ranks #449 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IOVA Stock Price and 52-Week Range

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) currently trades at $3.79. The stock lost $0.22 (5.5%) in the most recent trading session. The 52-week high for IOVA is $5.42, which means the stock is currently trading -30.1% from its annual peak. The 52-week low is $1.64, putting the stock 131.3% above its annual trough. Recent trading volume was 44.6M shares, indicating strong institutional interest and high liquidity.

Is IOVA Overvalued or Undervalued? — Valuation Analysis

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.95x, versus the sector average of 2.75x. The price-to-sales ratio is 5.81x, compared to 1.66x for the average Healthcare stock.

At current multiples, IOVANCE BIOTHERAPEUTICS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

IOVANCE BIOTHERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -57.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -44.5% versus the sector average of -33.1%.

On a margin basis, IOVANCE BIOTHERAPEUTICS, INC. reports gross margins of 19.9%, compared to 71.5% for the sector. The operating margin is -182.1% (sector: -66.1%). Net profit margin stands at -174.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 116.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IOVA Debt, Balance Sheet, and Financial Health

IOVANCE BIOTHERAPEUTICS, INC. has a debt-to-equity ratio of 29.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.41x, indicating strong short-term liquidity. Total debt on the balance sheet is $1M. Cash and equivalents stand at $158M.

IOVA has a beta of 1.68, meaning it is more volatile than the broader market — a $10,000 investment in IOVA would be expected to move 68.0% more than the S&P 500 on any given day. The stability factor score for IOVANCE BIOTHERAPEUTICS, INC. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

IOVANCE BIOTHERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $235M and earnings per share (EPS) of $-0.25. Net income for the quarter was $-403M. Gross margin was 19.9%. Operating income came in at $-419M.

In Q3 2025, IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $67M and earnings per share (EPS) of $-0.25. Net income for the quarter was $-91M. Gross margin was 43.0%. Revenue grew 15.2% year-over-year compared to Q3 2024. Operating income came in at $-95M.

In Q2 2025, IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $60M and earnings per share (EPS) of $-0.33. Net income for the quarter was $-112M. Gross margin was 5.5%. Revenue grew 92.7% year-over-year compared to Q2 2024. Operating income came in at $-114M.

In Q1 2025, IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $49M and earnings per share (EPS) of $-0.36. Net income for the quarter was $-116M. Gross margin was -0.9%. Revenue grew 6798.5% year-over-year compared to Q1 2024. Operating income came in at $-121M.

Over the past 8 quarters, IOVANCE BIOTHERAPEUTICS, INC. has demonstrated a growth trajectory, with revenue expanding from $715,000 to $235M. Investors analyzing IOVA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IOVA Dividend Yield and Income Analysis

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IOVA Momentum and Technical Analysis Profile

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a momentum factor score of 62/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

IOVA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, IOVANCE BIOTHERAPEUTICS, INC. (IOVA) ranks #449 out of 838 stocks based on the Blank Capital composite score. This places IOVA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IOVA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IOVA vs S&P 500 (SPY) comparison to assess how IOVANCE BIOTHERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.

IOVA Next Earnings Date

No upcoming earnings date has been announced for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IOVA? — Investment Thesis Summary

The quantitative profile for IOVANCE BIOTHERAPEUTICS, INC. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. Price momentum is positive at 62/100, suggesting the trend favors buyers. High volatility (stability score 19/100) increases portfolio risk.

In summary, IOVANCE BIOTHERAPEUTICS, INC. (IOVA) earns a Reduce rating with a composite score of 34.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IOVA stock.

Related Resources for IOVA Investors

Explore more research and tools: IOVA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IOVA head-to-head with peers: IOVA vs AZN, IOVA vs SLGL, IOVA vs VMD.